Market Overview

UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review

Related PFE
Markets Little Changed Ahead Of 4th Of July Break
Barclays Increases Pfizer Price Target
In Pursuit of Shire, AbbVie Eyes Lower Taxes in UK (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), but lowered the price target from $33.00 to $32.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Pfizer closed on Thursday at $27.48.

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free